Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758351 | 0.80 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL28569244 | 0.80 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL27293604 | 0.80 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL3751013 | 0.80 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL11068477 | 0.80 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL3750773 | 0.80 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL3745865 | 0.80 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL3757135 | 0.80 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL16073060 | 0.79 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 | |
| SCHEMBL16089344 | 0.79 | HTT (0.51) | HTTMAPTKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3342765-B1 | CATHEPSIN K INHIBITOR AND APPLICATION THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-09-15 | — | — | EP | disclosed |
| CN-107922315-B | Cathepsin K inhibitors and uses thereof | 广东东阳光药业有限公司 | 2021-03-26 | — | — | CN | disclosed |
| CN-106939248-B | Water-based carbon deposit cleaning composition for automobile | Foshan city cloud Technology Co. Ltd. (CN) | 2019-12-10 | — | — | CN | disclosed |
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| EP-3342765-A1 | CATHEPSIN K INHIBITOR AND APPLICATION THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2018-07-04 | — | — | EP | disclosed |
| EP-3204009-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090062550-A1 | Process for the Large Scale Production of Rizatriptan Benzoate | MATRIX LABORATORIES LTD (IN) | 2009-03-05 | — | — | US | disclosed |
| EP-1951713-A1 | PROCESS FOR THE LARGE SCALE PRODUCTION OF RIZATRIPTAN BENZOATE | Matrix Laboratories Ltd (IN) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007054979-A1 | PROCESS FOR THE LARGE SCALE PRODUCTION OF RIZATRIPTAN BENZOATE | MATRIX LABORATORIES LTD (IN) | 2007-05-18 | — | — | WO | disclosed |
| CN-1060479-C | Preparation method for imidazole derivatives | MERCK SHARP & DOHME (GB) | 2001-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | HTT 245/4885MAPT 3263/4885KMT2A 4081/4885 |
| US-20090062550-A1 | Process for the Large Scale Production of Rizatriptan Benzoate | DPP4, HTR3A, SI | HTT 2490/4885MAPT 1237/4885KMT2A 1648/4885 |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | HTT 231/4885MAPT 16/4885KMT2A 4527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.